tradingkey.logo
Search
Markets
Watchlist
News
Analysis
Tools
Stock Screener
English
繁体中文
ไทย
Tiếng việt
简体中文
Español
Português
Deutsch
한국어
日本語
tradingkey.logo
Search

Amneal Pharmaceuticals Inc

AMRX
Add to Watchlist
20.160USD
+1.450+7.75%
Close 09-21 16:00（ET）
6.44BMarket Cap
51.99P/E TTM
After-hours 17:29 (ET)20.000USD-0.205-1.01%

Amneal Pharmaceuticals Inc

20.160
+1.450+7.75%
Overview
Financials
Stock Score
Technical
Forecast
Ownership
Dividends
Profile
Discussions
Financial SummaryIncome StatementBalance SheetCash Flow StatementRevenueEarningsCompany ValuationRisk Assessment

Overview

Financials

Stock Score

Technical

Forecast

Ownership

Dividends

Profile

Discussions

Financial SummaryIncome StatementBalance SheetCash Flow StatementRevenueEarningsCompany ValuationRisk Assessment

AMRX Financials

See Amneal Pharmaceuticals Inc's financials through an all-in-one data dashboard designed for smart investors. This provides you with financial analysis by organizing complex financial statements into customizable views. Access the latest annual financial report or break down performance quarter-by-quarter using the income statement, balance sheet, and cash flow statement. With real-time financial indicators at your fingertips, monitoring a company's market health over time has never been easier.

Key Financial Ratios

Market Cap
6.44B
Dividend TTM
0.00
P/E TTM
51.99
EPS TTM
0.39
Revenue
3.02B
Net Profit
-116.89M
ROE
-155.38%
ROA
5.25%

Amneal Pharmaceuticals Inc Earnings Date

Latest Release
Jul 30, 2026
EPS / Forecast
0.18/0.22
Revenue / Forecast
796.20M/768.21M

Financial Statement Highlights

Quarterly
Quarterly+Annual
Quarterly
Annual
FY2026Q2
FY2026Q1
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021Q4
FY2021Q3
Financial Indicators
EPS
152.83%0.18
402.42%0.20
211.20%0.11
1608.00%0.01
268.49%0.07
113.15%0.04
75.14%-0.10
-100.80%0.00
-74.98%0.02
-553.46%-0.30
-1311.01%-0.40
--0.06
--0.08
---0.05
---0.03
---0.83
----
----
----
----
Revenue
9.89%796.20M
3.90%722.52M
11.47%814.32M
11.68%784.51M
3.24%724.51M
5.50%695.42M
18.40%730.52M
13.29%702.47M
17.15%701.78M
18.23%659.19M
1.18%616.98M
13.65%620.04M
7.10%599.05M
12.04%557.54M
13.57%609.76M
3.21%545.56M
4.54%559.36M
0.92%497.63M
5.27%536.90M
1.79%528.59M
Net Profit
157.22%57.66M
410.50%62.26M
212.85%35.08M
1618.59%2.37M
273.99%22.42M
113.31%12.20M
68.49%-31.08M
-101.61%-156.00K
-49.70%5.99M
-1219.93%-91.64M
-2176.69%-98.65M
460.06%9.68M
109.86%11.92M
-222.03%-6.94M
32.05%-4.33M
36.54%-2.69M
-931.32%-120.81M
-132.15%-2.16M
-109.98%-6.38M
52.79%-4.24M
Net Margin
77.89%8.74%
204.96%10.80%
314.40%6.09%
38.09%2.31%
105.47%4.92%
128.57%3.54%
81.23%-2.84%
-58.55%1.67%
-51.72%2.39%
-584.40%-12.39%
-1474.79%-15.13%
--4.04%
--4.96%
---1.81%
---0.96%
---15.53%
----
----
----
----
Gross Margin
6.34%42.01%
20.41%44.31%
1.42%36.50%
-8.99%34.92%
10.93%39.51%
1.89%36.80%
16.96%35.98%
2.32%38.37%
-3.03%35.62%
13.00%36.11%
-15.00%30.77%
--37.50%
--36.73%
--31.96%
--36.20%
--35.89%
----
----
----
----
Debt to assets ratio
-2.13%72.25%
-1.40%74.29%
-1.66%71.51%
-2.46%73.14%
-3.11%73.83%
-3.34%75.35%
-6.53%72.72%
0.47%74.98%
0.59%76.19%
1.13%77.95%
6.10%77.80%
--74.63%
--75.74%
--77.08%
--73.33%
--72.31%
----
----
----
----
Income Statement
Revenue
9.89%796.20M
3.90%722.52M
11.47%814.32M
11.68%784.51M
3.24%724.51M
5.50%695.42M
18.40%730.52M
13.29%702.47M
17.15%701.78M
18.23%659.19M
1.18%616.98M
13.65%620.04M
7.10%599.05M
12.04%557.54M
13.57%609.76M
3.21%545.56M
4.54%559.36M
0.92%497.63M
5.27%536.90M
1.79%528.59M
Operating profit
30.33%145.98M
54.78%148.27M
46.67%114.50M
-19.85%70.37M
16.20%112.01M
12.46%95.80M
127.87%78.07M
13.75%87.80M
27.13%96.39M
130.35%85.18M
-55.36%34.26M
73.44%77.19M
34.36%75.82M
65.50%36.98M
101.10%76.75M
-22.26%44.51M
-21.75%56.43M
-54.47%22.34M
51.31%38.17M
58.25%57.25M
Net Profit
157.22%57.66M
410.50%62.26M
212.85%35.08M
1618.59%2.37M
273.99%22.42M
113.31%12.20M
68.49%-31.08M
-101.61%-156.00K
-49.70%5.99M
-1219.93%-91.64M
-2176.69%-98.65M
460.06%9.68M
109.86%11.92M
-222.03%-6.94M
32.05%-4.33M
36.54%-2.69M
-931.32%-120.81M
-132.15%-2.16M
-109.98%-6.38M
52.79%-4.24M
Balance Sheet
Current assets
22.86%1.95B
19.03%1.80B
20.37%1.91B
21.49%1.84B
6.68%1.58B
9.45%1.51B
15.24%1.59B
3.93%1.51B
4.48%1.49B
5.56%1.38B
-2.41%1.38B
2.55%1.46B
-8.48%1.42B
-5.93%1.31B
-7.12%1.41B
-9.58%1.42B
-0.63%1.55B
-10.90%1.39B
-2.03%1.52B
1.72%1.57B
Total current liabilities
-20.23%883.19M
-32.33%728.05M
-21.96%881.63M
-21.28%862.11M
-0.65%1.11B
28.94%1.08B
33.45%1.13B
43.99%1.10B
43.35%1.11B
18.57%834.39M
12.46%846.60M
-7.02%760.60M
-21.72%777.35M
16.89%703.71M
11.16%752.80M
22.58%818.00M
47.59%993.06M
-5.45%602.04M
0.05%677.24M
-0.08%667.34M
Total assets
10.33%3.78B
5.20%3.54B
5.05%3.68B
4.01%3.60B
-2.48%3.42B
-2.64%3.37B
0.83%3.50B
-6.13%3.46B
-5.16%3.51B
-4.69%3.46B
-8.60%3.47B
-4.83%3.69B
-8.43%3.70B
-6.75%3.63B
-3.56%3.80B
-2.53%3.87B
0.46%4.04B
-1.80%3.89B
-1.66%3.94B
-1.56%3.97B
Total liabilities
5.88%3.74B
4.72%3.59B
3.84%3.75B
4.37%3.71B
-0.90%3.54B
-2.71%3.42B
4.59%3.61B
0.61%3.55B
0.49%3.57B
0.80%3.52B
-4.50%3.45B
-3.99%3.53B
-8.23%3.55B
0.30%3.49B
1.19%3.62B
2.46%3.68B
6.49%3.87B
-3.11%3.48B
-2.41%3.57B
-2.66%3.59B
Total equity
129.35%33.02M
22.60%-45.97M
34.87%-71.33M
-17.51%-109.95M
-95.75%-112.53M
6.66%-59.39M
-647.26%-109.51M
-160.66%-93.57M
-138.13%-57.49M
-147.25%-63.63M
-89.12%20.01M
-20.62%154.24M
-12.85%150.77M
-66.95%134.67M
-49.87%183.98M
-49.29%194.29M
-55.67%172.99M
11.10%407.41M
6.39%366.97M
10.04%383.17M
Cash Flow Statement
Net operating income
-125.35%-21.24M
-461.00%-26.74M
10.36%130.31M
-16.45%118.45M
111.36%83.82M
267.98%7.41M
-13.06%118.08M
74.20%141.77M
449.55%39.66M
-103.16%-4.41M
683.13%135.82M
-13.02%81.39M
90.96%-11.35M
16.09%139.71M
-136.82%-23.29M
13.61%93.57M
-141.70%-125.52M
-18.76%120.34M
-40.30%63.26M
83.95%82.36M
Net investment
-362.36%-122.74M
-21.98%-21.71M
-183.04%-45.45M
-8.46%-22.46M
-310.63%-26.55M
9.93%-17.80M
49.33%-16.06M
-53.70%-20.71M
47.37%-6.46M
-68.36%-19.76M
-176.40%-31.69M
72.68%-13.48M
23.78%-12.28M
87.95%-11.74M
86.82%-11.47M
-324.07%-49.33M
80.56%-16.12M
-667.31%-97.39M
-173.53%-86.97M
21.30%-11.63M
Net financing
290.37%79.36M
-50.78%-59.05M
83.47%-10.12M
164.37%59.44M
-18.81%-41.69M
-69.15%-39.17M
39.30%-61.20M
-6.65%-92.35M
-186.28%-35.09M
-79.50%-23.16M
-354.87%-100.83M
-87.69%-86.58M
-152.72%-12.26M
79.05%-12.90M
26.96%-22.17M
-5.92%-46.13M
161.07%23.25M
-135.46%-61.57M
-169.01%-30.35M
-194.13%-43.55M

Revenue

By Business

Period:
No Data

By Region

Period:
No Data

FAQs

What is the total revenue of Amneal Pharmaceuticals Inc?

According to Amneal Pharmaceuticals Inc's FY2025 earnings report, its total revenue reached 3.02B, with a year-on-year change of 2.79B.

What are the current assets of Amneal Pharmaceuticals Inc?

According to Amneal Pharmaceuticals Inc's FY2025 earnings report, its current assets were 1.91B, with a year-on-year change of 20.37.

What are the total assets of Amneal Pharmaceuticals Inc?

According to Amneal Pharmaceuticals Inc's FY2025 earnings report, its total assets of Amneal Pharmaceuticals Inc were 3.68B, with a year-on-year change of 5.05.

What are the total liabilities of Amneal Pharmaceuticals Inc?

According to Amneal Pharmaceuticals Inc's FY2025 earnings report, its total liabilities of Amneal Pharmaceuticals Inc were 3.75B, with a year-on-year change of 3.84.

What is the total equity of Amneal Pharmaceuticals Inc?

According to Amneal Pharmaceuticals Inc's FY2025 earnings report, its total equity of Amneal Pharmaceuticals Inc was -71.33M, with a year-on-year change of 34.87.

What is the net operating income of Amneal Pharmaceuticals Inc?

According to Amneal Pharmaceuticals Inc's FY2025 earnings report, its net operating income of Amneal Pharmaceuticals Inc was 397.91M, with a year-on-year change of 14.53.

What is the net investment of Amneal Pharmaceuticals Inc?

According to Amneal Pharmaceuticals Inc's FY2025 earnings report, its net investment of Amneal Pharmaceuticals Inc was -112.26M, with a year-on-year change of -78.21.

What is the net financing of Amneal Pharmaceuticals Inc?

According to Amneal Pharmaceuticals Inc's FY2025 earnings report, its net financing of Amneal Pharmaceuticals Inc was -31.53M, with a year-on-year change of 85.11.

What is the Earnings Per Share (EPS) of Amneal Pharmaceuticals Inc?

According to Amneal Pharmaceuticals Inc's FY2025 earnings report, its Earnings Per Share (EPS) was 0.23, with a year-on-year change of 160.78.

What is the net income of Amneal Pharmaceuticals Inc?

According to Amneal Pharmaceuticals Inc's FY2025 earnings report, its net income was 72.06M, with a year-on-year change of 161.65.

What is the net margin of Amneal Pharmaceuticals Inc?

According to Amneal Pharmaceuticals Inc's FY2025 earnings report, its net profit margin was 4.24, with a year-on-year change of 260.28.

What is the gross margin of Amneal Pharmaceuticals Inc?

According to Amneal Pharmaceuticals Inc's FY2025 earnings report, its gross margin was 36.88, with a year-on-year change of 0.98.

What is the debt-to-asset ratio of Amneal Pharmaceuticals Inc?

According to Amneal Pharmaceuticals Inc's FY2025 earnings report, its debt-to-asset ratio was 71.51, with a year-on-year change of -1.66.

What is the Return on Assets (ROA) of Amneal Pharmaceuticals Inc?

According to Amneal Pharmaceuticals Inc's FY2025 earnings report, its Return on Assets (ROA) was 3.56, with a year-on-year change of 268.21.

What is the operating profit of Amneal Pharmaceuticals Inc?

According to Amneal Pharmaceuticals Inc's FY2025 earnings report, its operating profit was 397.91M, with a year-on-year change of 14.53.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.
General Terms of Use
Privacy Policy
Cookie Policy